MENU
+Compare
PDSB
Stock ticker: NASDAQ
AS OF
Dec 26, 10:46 AM (EDT)
Price
$0.93
Change
+$0.04 (+4.49%)
Capitalization
48.88M

PDSB PDS Biotechnology Corp Forecast, Technical & Fundamental Analysis

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States... Show more

PDSB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PDSB with price predictions
Dec 24, 2025

PDSB in +2.60% Uptrend, advancing for three consecutive days on December 22, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PDSB advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

PDSB moved above its 50-day moving average on December 24, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PDSB crossed bullishly above the 50-day moving average on December 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PDSB moved out of overbought territory on December 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on December 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PDSB broke above its upper Bollinger Band on December 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PDSB entered a downward trend on December 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.171) is normal, around the industry mean (26.541). P/E Ratio (0.000) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (311.015).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PDSB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PDSB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PDSB is expected to report earnings to fall 7.00% to -17 cents per share on March 26

PDS Biotechnology Corp PDSB Stock Earnings Reports
Q4'25
Est.
$-0.18
Q3'25
Beat
by $0.02
Q2'25
Beat
by $0.01
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.10
The last earnings report on November 13 showed earnings per share of -18 cents, beating the estimate of -20 cents. With 151.63K shares outstanding, the current market capitalization sits at 48.88M.
A.I. Advisor
published General Information

General Information

a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
303A College Road
Phone
+1 800 208-3343
Employees
25
Web
https://www.pdsbiotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MBXBF0.16N/A
N/A
Microbix Biosystems Inc.
SJMHY1.59N/A
N/A
SJM Holdings Ltd.
WDGJF0.33N/A
N/A
Wood Group (John) Plc.
CNLTN33.35N/A
N/A
Connecticut Light & Power Co. (The)
BPIRY8.26-0.61
-6.88%
Piraeus Financial Holdings S.A.

PDSB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+2.68%
AXON - PDSB
43%
Loosely correlated
+0.02%
RGNX - PDSB
43%
Loosely correlated
+0.77%
RXRX - PDSB
41%
Loosely correlated
+0.92%
ALGS - PDSB
40%
Loosely correlated
+5.73%
XNCR - PDSB
40%
Loosely correlated
-0.13%
More